Steroid minimization in liver transplant recipients: Impact on hepatitis C recurrence and post-transplant diabetes

Abhinav Humar, Shaina Crotteau, Angelika C Gruessner, Raja Kandaswamy, Rainer W G Gruessner, William Payne, John Lake

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoimmune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%, p = 0.004). Conclusion: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.

Original languageEnglish (US)
Pages (from-to)526-531
Number of pages6
JournalClinical Transplantation
Volume21
Issue number4
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Hepatitis C
Prednisone
Steroids
Transplants
Recurrence
Liver
Control Groups
Tacrolimus
Immunosuppression
Tissue Donors
Biopsy
Cold Ischemia
Autoimmune Hepatitis
Graft Survival
Transplant Recipients
Liver Diseases
Survival Rate
Morbidity
Kidney
Antibodies

Keywords

  • Immunosuppression
  • Liver transplant
  • Post-transplant diabetes
  • Steroid avoidance

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Steroid minimization in liver transplant recipients : Impact on hepatitis C recurrence and post-transplant diabetes. / Humar, Abhinav; Crotteau, Shaina; Gruessner, Angelika C; Kandaswamy, Raja; Gruessner, Rainer W G; Payne, William; Lake, John.

In: Clinical Transplantation, Vol. 21, No. 4, 07.2007, p. 526-531.

Research output: Contribution to journalArticle

Humar, Abhinav ; Crotteau, Shaina ; Gruessner, Angelika C ; Kandaswamy, Raja ; Gruessner, Rainer W G ; Payne, William ; Lake, John. / Steroid minimization in liver transplant recipients : Impact on hepatitis C recurrence and post-transplant diabetes. In: Clinical Transplantation. 2007 ; Vol. 21, No. 4. pp. 526-531.
@article{2a22922abf394edaa89cab266ae45ad5,
title = "Steroid minimization in liver transplant recipients: Impact on hepatitis C recurrence and post-transplant diabetes",
abstract = "Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoimmune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11{\%} in the RDP group vs. 12{\%} in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56{\%} of the control group hepatitis C positive recipients vs. 39{\%} in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12{\%} vs. 32{\%}, p = 0.004). Conclusion: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.",
keywords = "Immunosuppression, Liver transplant, Post-transplant diabetes, Steroid avoidance",
author = "Abhinav Humar and Shaina Crotteau and Gruessner, {Angelika C} and Raja Kandaswamy and Gruessner, {Rainer W G} and William Payne and John Lake",
year = "2007",
month = "7",
doi = "10.1111/j.1399-0012.2007.00683.x",
language = "English (US)",
volume = "21",
pages = "526--531",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Steroid minimization in liver transplant recipients

T2 - Impact on hepatitis C recurrence and post-transplant diabetes

AU - Humar, Abhinav

AU - Crotteau, Shaina

AU - Gruessner, Angelika C

AU - Kandaswamy, Raja

AU - Gruessner, Rainer W G

AU - Payne, William

AU - Lake, John

PY - 2007/7

Y1 - 2007/7

N2 - Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoimmune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%, p = 0.004). Conclusion: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.

AB - Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoimmune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%, p = 0.004). Conclusion: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.

KW - Immunosuppression

KW - Liver transplant

KW - Post-transplant diabetes

KW - Steroid avoidance

UR - http://www.scopus.com/inward/record.url?scp=34547438879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547438879&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2007.00683.x

DO - 10.1111/j.1399-0012.2007.00683.x

M3 - Article

C2 - 17645714

AN - SCOPUS:34547438879

VL - 21

SP - 526

EP - 531

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -